A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed advanced endometrial carcinoma with any histology,
including:

- Clear cell and serous papillary carcinoma

- Surgical stage III disease, including:

- Positive adnexa

- Tumor invading the serosa

- Positive pelvic and/or paraaortic nodes

- Involvement of bowel mucosa

- Intraabdominal metastases

- Positive pelvic washings

- Vaginal involvement within the radiation port

- Must have had prior surgery, including hysterectomy and bilateral
salpingo-oophorectomy

- Tumor maximally debulked to a maximum residual diameter of no greater than 2 cm

- Paraaortic lymph node sampling allowed

- If positive, must have negative chest CT scan

- No recurrent disease

- No parenchymal liver metastases

- No disease outside the abdomen

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- GOG 0-2

Life expectancy:

- At least 3 months

Hematopoietic:

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than 1.5 times normal

- SGOT/SGPT no greater than 3 times normal

- Alkaline phosphatase no greater than 3 times normal

Renal:

- Creatinine no greater than 1.6 mg/dL

Cardiovascular:

- LVEF at least 50% within 6 months of study entry

Other:

- No other prior or concurrent malignancy within the past 5 years except adequately
treated nonmelanoma skin cancer

- No serious comorbid illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

- No prior pelvic or abdominal radiotherapy

- No prior radiotherapy for prior malignancy

Surgery:

- See Disease Characteristics